BioCentury | Oct 16, 2020
Product Development

Recent Phase III disappointment aside, the heart failure pipeline holds plenty to look forward to

...two diuretic mechanisms. Finerenone is an oral mineralocorticoid receptor...
BioCentury | Jul 19, 2019
Regulation

A half step forward for heart failure as FDA guidance leaves key question unanswered

...with mortality and safety data. For example, safety profiles of ACE inhibitors, angiotensin receptor blockers, mineralocorticoid receptor...
BioCentury | Mar 2, 2018
Clinical News

Daiichi submits Japanese application for esaxerenone

...million milestone payment to the South San Francisco company. The candidate is an oral non-steroidal mineralocorticoid receptor...
...deal, Daiichi has exclusive, worldwide rights from Exelixis to develop and commercialize therapies targeting the mineralocorticoid receptor...
...Sankyo Co. Ltd. (Tokyo:4568), Tokyo, Japan Product: Esaxerenone (CS-3150) Business: Cardiovascular Chris Lieu CS-3150 esaxerenone Daiichi Sankyo Co. Ltd. Exelixis Inc. Mineralocorticoid receptor...
BioCentury | Feb 28, 2018
Company News

Exelixis shares dip after 4Q earnings

...million milestone payment to the South San Francisco company. The candidate is an oral non-steroidal mineralocorticoid receptor...
...deal, Daiichi has exclusive, worldwide rights from Exelixis to develop and commercialize therapies targeting the mineralocorticoid receptor...
...including esaxerenone. Chris Lieu Cabometyx cabozantinib Cometriq esaxerenone Daiichi Sankyo Co. Ltd. Exelixis Inc. Ipsen Group Takeda Pharmaceutical Co. Ltd. AXL receptor tyrosine kinase (AXL) (UFO) Mineralocorticoid receptor Vascular...
BioCentury | Jan 5, 2018
Financial News

Chinese biotech KBP raises $76 million series A

...Elite Capital. KBP plans to start Phase IIb testing this year of KBP-5074, a non-steroidal mineralocorticoid receptor...
BioCentury | Jan 5, 2018
Financial News

Chinese biotech KBP raises $76 million series A

...Elite Capital. KBP plans to start Phase IIb testing this year of KBP-5074, a non-steroidal mineralocorticoid receptor...
BioCentury | Sep 29, 2017
Clinical News

Daiichi planning Japanese application for hypertension candidate

...In 1Q18, Daiichi plans to submit a regulatory application in Japan for the oral non-steroidal mineralocorticoid receptor...
...a 2006 deal, Daiichi has exclusive, worldwide rights to develop and commercialize therapies targeting the mineralocorticoid receptor...
...Ltd. (Tokyo:4568), Tokyo, Japan Product: Esaxerenone (CS-3150) Business: Cardiovascular Molecular target: Mineralocorticoid receptor Description: Oral non-steroidal mineralocorticoid receptor...
BioCentury | Sep 25, 2017
Clinical News

Daiichi planning Japanese application for hypertension candidate

...In 1Q18, Daiichi plans to submit a regulatory application in Japan for the oral non-steroidal mineralocorticoid receptor...
...a 2006 deal, Daiichi has exclusive, worldwide rights to develop and commercialize therapies targeting the mineralocorticoid receptor...
...Extra, March 20, 2006) . Inspra, a small molecule that blocks aldosterone binding to the mineralocorticoid receptor...
BioCentury | Oct 3, 2016
Clinical News

Esaxerenone: Phase III started

...a deal granting the pharma exclusive, worldwide rights to develop and commercialize therapies targeting the mineralocorticoid receptor...
...CS-3150 , XL550 ) Business: Cardiovascular Molecular target: Mineralocorticoid receptor Description: Small molecule antagonist of the mineralocorticoid receptor...
BioCentury | Nov 16, 2015
Product Development

Myo my

...top of background therapies including angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers, beta blockers and mineralocorticoid receptor...
Items per page:
1 - 10 of 33